MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other...

VANCOUVER, BC, Sept. 29, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“), has granted an aggregate of 234,192 restricted...

VANCOUVER, BC, Sept. 9, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce,...